Cargando…

T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma

Despite impressive progress, a significant portion of patients still experience primary or secondary resistance to chimeric antigen receptor (CAR) T-cell immunotherapy for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). The mechanism of primary resistance involves T-cell extrinsic and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jiachen, Shen, Kefeng, Mu, Wei, Li, Weigang, Zhang, Meilan, Zhang, Wei, Li, Zhe, Ge, Tong, Zhu, Zhoujie, Zhang, Shangkun, Chen, Caixia, Xing, Shugang, Zhu, Li, Chen, Liting, Wang, Na, Huang, Liang, Li, Dengju, Xiao, Min, Zhou, Jianfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094425/ https://www.ncbi.nlm.nih.gov/pubmed/35572515 http://dx.doi.org/10.3389/fimmu.2022.873789

Ejemplares similares

Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy
por: Wei, Jia, et al.
Publicado: (2020)

MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy
por: Jin, Jin, et al.
Publicado: (2023)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT
por: Wei, Jia, et al.
Publicado: (2022)

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
por: Huang, Lefu, et al.
Publicado: (2022)

MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy
por: Wang, Jiachen, et al.
Publicado: (2021)

Clinical Utility of Droplet Digital PCR to Monitor BCR-ABL1 Transcripts of Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Post-chimeric Antigen Receptor19/22 T-Cell Cocktail Therapy
por: Guan, Yuqi, et al.
Publicado: (2021)

Upregulation of CD22 by Chidamide promotes CAR T cells functionality
por: Yang, Xin, et al.
Publicado: (2021)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
por: Sun, Yao, et al.
Publicado: (2021)

A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform
por: Zhang, Wei, et al.
Publicado: (2021)

Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
por: Wei, Jia, et al.
Publicado: (2019)

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity
por: Shi, Jiangzhou, et al.
Publicado: (2021)

Monitoring anti‐CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction
por: Cheng, Jiali, et al.
Publicado: (2022)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
por: Liu, Sining, et al.
Publicado: (2023)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Clinical Features and MicroRNA Expression Patterns Between AML Patients With DNMT3A R882 and Frameshift Mutations
por: Yang, Li, et al.
Publicado: (2019)

A novel full-human CD22-CAR T cell therapy with potent activity against CD22(low) B-ALL
por: Tan, Yue, et al.
Publicado: (2021)

A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
por: Fergusson, Nathan J., et al.
Publicado: (2023)

Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma
por: Wu, Jiaying, et al.
Publicado: (2021)

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity
por: Zhang, Shangkun, et al.
Publicado: (2022)

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
por: Zhang, Ying, et al.
Publicado: (2021)

Inflammatory abrasion of hematopoietic stem cells: a candidate clue for the post-CAR-T hematotoxicity?
por: Sun, Ting, et al.
Publicado: (2023)

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA
por: Luo, Wenjing, et al.
Publicado: (2023)

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
por: Zhu, Haibo, et al.
Publicado: (2021)

Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis
por: Li, Lili, et al.
Publicado: (2022)

A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy
por: Mu, Wei, et al.
Publicado: (2022)

Anti-CD19 CAR T-cell consolidation therapy combined with CD19(+) feeding T cells and TKI for Ph(+) acute lymphoblastic leukemia
por: Chen, Li-Yun, et al.
Publicado: (2023)

CD166-specific CAR-T cells potently target colorectal cancer cells
por: He, Shuai, et al.
Publicado: (2022)

CD19/CD22 chimeric antigen receptor (CAR) T-cell cocktail therapy following autologous transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma on (18)F-FDG PET/CT: a case description
por: Zhou, Yeye, et al.
Publicado: (2023)

CD58 loss in tumor cells confers functional impairment of CAR T cells
por: Yan, Xin, et al.
Publicado: (2022)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
por: Xue, YuanBo, et al.
Publicado: (2021)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells
por: Zhang, Yuanyuan, et al.
Publicado: (2023)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

CD137 deficiency because of two novel biallelic TNFRSF9 mutations in a patient presenting with severe EBV‐associated lymphoproliferative disease
por: Shen, Kefeng, et al.
Publicado: (2023)

Advances in Universal CAR-T Cell Therapy
por: Lin, Haolong, et al.
Publicado: (2021)

Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia
por: Cheng, Jiali, et al.
Publicado: (2023)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a2e3dm9mv2d2691rfnueunr87d